Disease Specific Services

Hematological Malignancies Program
10 Union Square East
New York, NY 10003
(212) 844-8282

More than 100,000 people in the United States are diagnosed each year with hematological malignancies, including non-Hodgkin's lymphoma, Hodgkin's disease, leukemia, and multiple myeloma. Increased understanding of the biology of these diseases has led to the development of new therapies that will soon be available to patients at Beth Israel's Cancer Center. The goal of the Hematological Malignancies Program is to offer patients access to a full spectrum of traditional and investigational therapies.

Among the clinical trials available to our patients are:

• A new monoclonal anti-body conjugated to a radiostope (Yttrium-90) to permit the delivery of targeted radiation oncology to patients with low-grade non-Hodgkin's lymphoma.

• A novel infusional chemotherapy regimen (EPOCH), administered in conjunction with the monoclonal anti-body Rituximab. This therapy is designed to enhance response rates and permit dose escalation of chemotherapy with reduced toxicity.

• A trial of a new vaccine designed to enhance the immune system for patients with low-grade non-Hodgkin's lymphoma.

• Cooperative group trials sponsored by the Southwest Oncology Group, Eastern Cooperative Oncology Group and the AIDS Malignancy Consortium, designed to assess new regimens in Hodgkin's Disease and non-Hodgkin's lymphoma.

top